guest ::
| Home > Institute Collections > W500 > Heparanase 2 (Hpa2) attenuates the growth of human sarcoma. > print |
| Home > Institute Collections > W500 > Heparanase 2 (Hpa2) attenuates the growth of human sarcoma. > print |
| 001 | 306247 | ||
| 005 | 20251118115713.0 | ||
| 024 | 7 | _ | |a 10.1016/j.matbio.2022.09.003 |2 doi |
| 024 | 7 | _ | |a pmid:36122821 |2 pmid |
| 024 | 7 | _ | |a 0945-053X |2 ISSN |
| 024 | 7 | _ | |a 1569-1802 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-02476 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Knani, Ibrahim |b 0 |
| 245 | _ | _ | |a Heparanase 2 (Hpa2) attenuates the growth of human sarcoma. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2022 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1763463404_1939186 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #DKFZ-MOST-Ca198# |
| 520 | _ | _ | |a The pro-tumorigenic properties of heparanase are well documented and established. In contrast, the role of heparanase 2 (Hpa2), a close homolog of heparanase, in cancer is not entirely clear. In carcinomas, Hpa2 is thought to attenuate tumor growth, possibly by inhibiting heparanase enzymatic activity. Here, we examine the role of Hpa2 in sarcoma, a group of rare tumors of mesenchymal origin, accounting for approximately 1% of all malignant tumors. Consistently, we found that overexpression of Hpa2 attenuates tumor growth while Hpa2 gene silencing results in bigger tumors. Mechanistically, attenuation of tumor growth by Hpa2 was associated with increased tumor stress conditions, involving ER stress, hypoxia, and JNK phosphorylation, leading to increased apoptotic cell death. In addition, overexpression of Hpa2 induces the expression of the p53 family member, p63 which, in sarcoma, functions to attenuate tumor growth. Moreover, we show that Hpa2 profoundly reduces stem cell characteristics of the sarcoma cells (stemness), most evident by failure of Hpa2 cells to grow as spheroids typical of cancer stem cells. Likewise, expression of CD44, a well-established cancer stem cell marker, was prominently decreased in Hpa2 cells. CD44 is also a cell surface receptor for hyaluronic acid (HA), a nonsulfated glycosaminoglycan that is enriched in connective tissues. Reduced expression of CD44 by Hpa2 may thus represent impaired cross-talk between Hpa2 and the extracellular matrix. Clinically, we found that Hpa2 is expressed by leiomyosarcoma tumor biopsies. Interestingly, nuclear localization of Hpa2 was associated with low-stage tumors. This finding opens a new direction in Hpa2 research. |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Heparanase 2 |2 Other |
| 650 | _ | 7 | |a Sarcoma |2 Other |
| 650 | _ | 7 | |a Stemness |2 Other |
| 650 | _ | 7 | |a Stress |2 Other |
| 650 | _ | 7 | |a Tumor growth |2 Other |
| 650 | _ | 7 | |a heparanase |0 EC 3.2.1.- |2 NLM Chemicals |
| 650 | _ | 7 | |a Glucuronidase |0 EC 3.2.1.31 |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Glucuronidase: genetics |2 MeSH |
| 650 | _ | 2 | |a Glucuronidase: metabolism |2 MeSH |
| 650 | _ | 2 | |a Sarcoma: genetics |2 MeSH |
| 650 | _ | 2 | |a Soft Tissue Neoplasms |2 MeSH |
| 650 | _ | 2 | |a Extracellular Matrix: metabolism |2 MeSH |
| 700 | 1 | _ | |a Yanku, Yifat |b 1 |
| 700 | 1 | _ | |a Gross-Cohen, Miriam |b 2 |
| 700 | 1 | _ | |a Ilan, Neta |b 3 |
| 700 | 1 | _ | |a Vlodavsky, Israel |b 4 |
| 773 | _ | _ | |a 10.1016/j.matbio.2022.09.003 |g Vol. 113, p. 22 - 38 |0 PERI:(DE-600)2005263-7 |p 22 - 38 |t Matrix biology |v 113 |y 2022 |x 0945-053X |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-10 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MATRIX BIOL : 2022 |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-10 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-10 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-10 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b MATRIX BIOL : 2022 |d 2024-12-10 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a I:(DE-He78)W500-20160331 |
| 980 | _ | _ | |a I:(DE-He78)W510-20160331 |
| 980 | 1 | _ | |a EXTERN4COORD |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|